tiprankstipranks
In this article:
Blurbs

Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and Lantern Pharma (LTRN)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cocrystal Pharma (COCPResearch Report) and Lantern Pharma (LTRNResearch Report) with bullish sentiments.

Cocrystal Pharma (COCP)

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cocrystal Pharma, with a price target of $5.00. The company’s shares closed last Monday at $0.55, close to its 52-week low of $0.47.

According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of 20.2% and a 32.3% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Onconova Therapeutics, and PDS Biotechnology.

Cocrystal Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $4.50, implying a 675.9% upside from current levels. In a report issued on January 31, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Lantern Pharma (LTRN)

In a report released today, Kyle Bauser from Colliers Securities reiterated a Buy rating on Lantern Pharma, with a price target of $29.00. The company’s shares closed last Monday at $6.78, close to its 52-week low of $5.45.

According to TipRanks.com, Bauser is a 1-star analyst with an average return of -0.7% and a 43.3% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Apollo Medical Holdings, Chembio Diagnostics, and Motus Gi Holdings.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lantern Pharma with a $29.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on COCP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed